Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK To Take Second Shot At The Rural Indian Market; Considering Customized Strategy

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - India's largest multinational drug maker GlaxoSmithKline is planning a big entry into the country's rural pharmaceutical market. An exhaustive plan is being hammered out to understand the dynamics of the rural medicine market so that GSK can position itself correctly in the intensely price-sensitive market segment
Advertisement

Related Content

GSK India Managing Director Hasit Joshipura: An Interview With PharmAsia News (Part 2 of 2)
GSK India Managing Director Hasit Joshipura: An Interview With PharmAsia News (Part 2 of 2)
GSK India Managing Director Hasit Joshipura On What Lies Ahead For India’s Largest Multinational Drug Company: An Interview With PharmAsia News (Part 2 of 2)
GSK Vows To Eradicate Lymphatic Filariasis By 2020
GSK India Managing Director Hasit Joshipura On What Lies Ahead For India’s Largest Multinational Drug Company: An Interview With PharmAsia News (Part 2 of 2)
GSK Vows To Eradicate Lymphatic Filariasis By 2020
Indian Govt Wants Drug Outlets In Every District
Novartis Designs “Arogya Parivar” Initiative To Reach India’s Rural Centers
Ranbaxy Claims Greatest Indian Market Share, Ahead of Cipla, GSK
PharmAsia News Notable Notes: GSK India Aims For Nine Product Launches In Two Years
Advertisement
UsernamePublicRestriction

Register

SC069698

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel